Journal of Biological Chemistry · 2011 · 205 citations · 46 references
MedicineCancer BiologyOncologyChemotherapyMolecular OncologyTumor ProgressionCancer Stem Cell BiologyCancer Stem CellsChemotherapy ResistanceMalignant NeoplasmsReactive Oxygen SpeciesStem Cell TumorigenicityCancer Cell SenescenceCancer Stem Cell - Mediated ResistanceCancer Stem Cell RadioresistanceCancer Stem Cell-mediated ResistanceCancer Stem-like CellsCd133 ExpressionMalignant Breast TumorsTherapy-resistant Cancer Stem Cells
Tumor recurrence after chemotherapy or radiation remains a major obstacle to successful cancer treatment. A subset of cancer cells, termed cancer stem cells, can elude conventional treatments and eventually regenerate a tumor that is more aggressive. Despite the large number of studies, molecular events that govern the emergence of aggressive therapy-resistant cells with stem cell properties after chemotherapy are poorly defined. The present study provides evidence for the rare escape of tumor cells from drug-induced cell death, after an intermediate stay in a non-cycling senescent stage followed by unstable multiplication characterized by spontaneous cell death. However, some cells appear to escape and generate stable colonies with an aggressive tumor stem cell-like phenotype. These cells displayed higher CD133 and Oct-4 expression. Notably, the drug-selected cells that contained low levels of reactive oxygen species (ROS) also showed an increase in antioxidant enzymes. Consistent with this in vitro experimental data, we observed lower levels of ROS in breast tumors obtained after neoadjuvant chemotherapy compared with samples that did not receive preoperative chemotherapy. These latter tissues also expressed enhanced levels of ROS defenses with enhanced expression of superoxide dismutase. Higher levels of Oct-4 and CD133 were also observed in tumors obtained after neoadjuvant chemotherapy. Further studies provided evidence for the stabilization of Nrf2 due to reduced 26 S proteasome activity and increased p21 association as the driving signaling event that contributes to the transition from a high ROS quiescent state to a low ROS proliferating stage in drug-induced tumor stem cell enrichment.
46
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
Identification of human brain tumour initiating cells
Sheila K. Singh, Cynthia Hawkins, Ian D. Clarke et al. · Nature · 2004 · 7.4K citations
Medicine, Cancer Biology, Oncology +11
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Nam W. Kim, Mieczyslaw A. Piatyszek, Karen R. Prowse et al. · Science · 1994 · 7.1K citations
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma, Diana Lee, Bihua Li et al. · Cell · 2010 · 2.8K citations · Full text